# TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

Source: https://onco.cc/trials/nct06453902/  
OnCo record `nct06453902` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TGRX-678 in chronic myeloid leukaemia, run by Shenzhen TargetRx Co., Ltd., now recruiting.

## Summary

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients is a phase 2 interventional study registered as NCT06453902 by Shenzhen TargetRx Co., Ltd., with 40 participants planned, started 2024-07-15 and due to reach its primary completion in 2026-06-30. Interventions recorded: TGRX-678.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06453902
- Phase: 2
- Setting: A Single-arm, Open-label, Multi-center Phase II Study Evaluating Efficacy and Safety of TGRX-678 in CML-AP Patients Relapsed or Refractory From 3rd-generation TKI Treatment
- Sponsor: Shenzhen TargetRx Co., Ltd.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06453902: https://clinicaltrials.gov/study/NCT06453902

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- companies: [Shenzhen TargetRx](https://onco.cc/companies/shenzhen-targetrx/)

---
JSON: https://onco.cc/api/v1/entities/nct06453902.json